DA-302168S

(1) To evaluate the safety and tolerability of DA-302168S tablets after multiple oral administration in overweight/obese subjects; (2) To evaluate the pharmacokinetic (PK) characteristics of DA-302168S tablets after multiple oral administration in overweight/obese subjects; (3) To evaluate the pharmacodynamic (PD) characteristics of DA-302168S tablets after multiple oral administration in overweight/obese subjects; (4) To evaluate the PK characteristics of DA-302168S tablets in overweight/obese subjects based on the PopPK analysis method; (5) To evaluate the correlation between exposure and effect of DA-302168S tablets; (6) To evaluate the effect of DA-302168S tablets on the QT interval in overweight/obese subjects.